Clinical Trial Detail

NCT ID NCT02750358
Title Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

triple-receptor negative breast cancer

Therapies

Enzalutamide

Age Groups: adult

No variant requirements are available.